Notebook

As Congress readied for recess, approaching the end of the 1996 fiscal year on October 1, it hurriedly passed several spending bills for fiscal year 1997. Some, such as the Veterans Administration, Housing and Urban Development, and Independent Agencies bills, included provisions for various R&D agencies, including the National Science Foundation and the National Aeronautics and Space Administration. Other agency budgets, such as that of the Department of Health and Human Services, weren't

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

As Congress readied for recess, approaching the end of the 1996 fiscal year on October 1, it hurriedly passed several spending bills for fiscal year 1997. Some, such as the Veterans Administration, Housing and Urban Development, and Independent Agencies bills, included provisions for various R&D agencies, including the National Science Foundation and the National Aeronautics and Space Administration. Other agency budgets, such as that of the Department of Health and Human Services, weren't finalized by the October 1 deadline and were lumped into a catch-all bill, the Omnibus Appropriations Bill. For many agencies, the congressional move was a welcome change from last year's series of continuing resolutions. NSF received a $3.27 billion budget, a 2 percent hike (or $50 million) over the FY 1996 level. "It's the first time in my memory over the last six years that we've had our budget passed before the fiscal year began," says David ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies